标题
How we manage adults with myelodysplastic syndrome
作者
关键词
-
出版物
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-10-01
DOI
10.1111/bjh.16206
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
- (2019) Marie Sébert et al. HAEMATOLOGICA
- Guadecitabine in myelodysplastic syndromes: promising but there is still progress to be made
- (2019) Lionel Adès et al. Lancet Haematology
- Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
- (2019) Guillermo Garcia-Manero et al. Lancet Haematology
- Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies
- (2018) Michael R. Savona et al. AMERICAN JOURNAL OF HEMATOLOGY
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
- (2018) Pierre Fenaux et al. LEUKEMIA
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of azacitidine is independent of molecular and clinical characteristics-an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
- (2018) Andrea Kuendgen et al. Oncotarget
- Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial
- (2018) Hagop M Kantarjian et al. Lancet Haematology
- Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review
- (2018) Sophie Park et al. BRITISH JOURNAL OF HAEMATOLOGY
- Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
- (2018) Nicholas J Short et al. Lancet Haematology
- Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
- (2017) Laurence Lodé et al. HAEMATOLOGICA
- Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
- (2017) Manja Meggendorfer et al. HAEMATOLOGICA
- Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
- (2017) Sophie Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
- (2017) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study
- (2017) Uwe Platzbecker et al. LANCET ONCOLOGY
- Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
- (2017) R. Coleman Lindsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
- (2017) Laurence Lodé et al. HAEMATOLOGICA
- Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
- (2017) Manja Meggendorfer et al. HAEMATOLOGICA
- Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
- (2017) Esther N Oliva et al. Lancet Haematology
- A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium
- (2017) L. R. Silverman et al. JOURNAL OF CLINICAL ONCOLOGY
- Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
- (2016) O. Kosmider et al. HAEMATOLOGICA
- A randomized phase II trial of azacitidine +/- epoetin- in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
- (2016) S. Thepot et al. HAEMATOLOGICA
- Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
- (2016) Valeria Santini et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
- (2016) M Mossner et al. LEUKEMIA
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
- (2016) O. Kosmider et al. HAEMATOLOGICA
- A randomized phase II trial of azacitidine +/- epoetin- in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents
- (2016) S. Thepot et al. HAEMATOLOGICA
- SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
- (2015) L. Malcovati et al. BLOOD
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
- (2015) D. P. Steensma et al. BLOOD
- Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
- (2015) Ronan T. Swords et al. BRITISH JOURNAL OF HAEMATOLOGY
- Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q
- (2015) M Heuser et al. LEUKEMIA
- Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
- (2015) A Toma et al. LEUKEMIA
- Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients
- (2015) S Jilg et al. LEUKEMIA
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
- (2014) R. Bejar et al. BLOOD
- Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
- (2014) Thomas Prebet et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation
- (2014) Rafael Bejar et al. JOURNAL OF CLINICAL ONCOLOGY
- Myelodysplastic syndromes
- (2014) Lionel Adès et al. LANCET
- Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial
- (2014) M Tobiasson et al. Blood Cancer Journal
- Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
- (2013) V. Santini et al. BLOOD
- Clinical and biological implications of driver mutations in myelodysplastic syndromes
- (2013) E. Papaemmanuil et al. BLOOD
- TP53mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis
- (2013) Austin G. Kulasekararaj et al. BRITISH JOURNAL OF HAEMATOLOGY
- Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia
- (2013) A Pellagatti et al. LEUKEMIA
- Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
- (2012) M. A. Sekeres et al. BLOOD
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
- (2012) P. L. Greenberg et al. BLOOD
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group
- (2012) Arjan A. van de Loosdrecht et al. LEUKEMIA & LYMPHOMA
- TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
- (2011) Martin Jädersten et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Clinical Effect of Point Mutations in Myelodysplastic Syndromes
- (2011) Rafael Bejar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
- (2010) R. Itzykson et al. BLOOD
- Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions
- (2010) Elaine M. Sloand et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care—SAKK 33/99
- (2010) Jakob R. Passweg et al. JOURNAL OF CLINICAL ONCOLOGY
- Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM
- (2010) Christian Rose et al. LEUKEMIA RESEARCH
- Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment
- (2009) T. M. Westers et al. BLOOD
- Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study
- (2009) E. P. Alessandrino et al. HAEMATOLOGICA
- Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
- (2009) Roger M. Lyons et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
- (2009) Hagop Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
- (2008) Aristoteles Giagounidis et al. ANNALS OF HEMATOLOGY
- Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia
- (2008) Azra Raza et al. CANCER
- Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial
- (2008) Sucha Nand et al. LEUKEMIA & LYMPHOMA
- Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide
- (2008) C. Kelaidi et al. LEUKEMIA RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started